Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 10/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL747250 | 1.00 | DAO (0.56) | DAOAXLNUDT1AURKAPARP1 | |
| SCHEMBL29486398 | 1.00 | DAO (0.56) | DAOAXLNUDT1AURKAPARP1 | |
| Trifluoroacetic Acid SCHEMBL29713497 | 0.86 | DAO (0.48) | DAORIPK1 | |
| SCHEMBL5794083 | 0.76 | DAO (0.47) | DAOAXLNUDT1RIPK1CCNB2 | |
| SCHEMBL4429036 | 0.74 | MAPT (0.50) | — | |
| SCHEMBL29498319 | 0.73 | DAO (0.53) | DAOAXLNUDT1AURKAPARP1 | |
| SCHEMBL126973 | 0.73 | DAO (0.53) | DAOAXLNUDT1AURKAPARP1 | |
| SCHEMBL491810 | 0.73 | PARP1 (0.42) | NUDT1AURKAPARP1 | |
| SCHEMBL5413200 | 0.73 | PARP1 (0.42) | NUDT1AURKAPARP1 | |
| Hydrochloric Acid SCHEMBL7181738 | 0.72 | DAO (0.51) | DAOAXLNUDT1AURKAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119177216-A | KRAS G12C inhibitor drug-resistant human pancreatic cancer cell, construction method and application thereof | 中山大学 | 2024-12-24 | — | — | CN | claimed |
| WO-2024175999-A2 | BENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2024-08-29 | — | — | WO | claimed |
| CN-122036626-A | Pyrimidine-2 (1H) -ketone derivative, pharmaceutical composition and application thereof | 上海青润医药科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4709853-A1 | METHODS OF PREVENTING ON-TARGET GENOTOXICITY INDUCED BY NUCLEASES | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-03-18 | — | — | EP | disclosed |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | IDEAYA BIOSCIENCES, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250381243-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| WO-2025242031-A1 | USE OF COMBINATION OF PYRIDO[2,3-D]PYRIMIDIN-2(1H)-ONE DERIVATIVE IN PREVENTING OR TREATING TUMOR DISEASE | 上海翰森生物医药科技有限公司 | 2025-11-27 | — | — | WO | disclosed |
| WO-2025242031-A1 | USE OF COMBINATION OF PYRIDO[2,3-D]PYRIMIDIN-2(1H)-ONE DERIVATIVE IN PREVENTING OR TREATING TUMOR DISEASE | 上海翰森生物医药科技有限公司 | 2025-11-27 | — | — | WO | disclosed |
| EP-4638457-A1 | HETEROCYCLES AND USES THEREOF | Kumquat Biosciences Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4041775-A1 | COMBINATION THERAPY FOR CANCERS WITH KRAS MUTATION | Cothera Bioscience, Inc. (KY) | 2022-08-17 | — | — | EP | disclosed |
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2022-07-07 | — | — | US | disclosed |
| WO-2022121839-A1 | PYRIDO[2,3-D]PYRIMIDIN-2(1H)-ONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-06-16 | — | — | WO | disclosed |
| WO-2022111521-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州多域生物技术有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2022106897-A2 | METHODS AND COMPOSITION FOR KRAS MODIFICATIONS | 2692372 ONTARIO, INC. (CA) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022076917-A1 | MODULATORS OF CELL PROLIFERATION AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | IDEAYA BIOSCIENCES, INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3978490-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2022-04-06 | — | — | EP | disclosed |
| CN-114269735-A | Dihydro or tetrahydro quinazoline compound and intermediate, preparation method and application thereof | 南京创济生物医药有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213100-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, NRAS, GNAQ | DAO 4577/4885AXL 2148/4885NUDT1 609/4885 |
| US-20250381243-A1 | HETEROCYCLES AND USES THEREOF | TP53, KRAS, HRAS | DAO 3985/4885AXL 635/4885NUDT1 1294/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | DAO 3983/4885AXL 3344/4885NUDT1 1635/4885 |
| US-20220106276-A1 | 2-OXOQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS | MAT2B, MAT2A, MAT1A | DAO 1164/4885AXL 4213/4885NUDT1 15/4885 |
| US-12497396-B2 | Nitrogen-containing heterocyclic derivatives, method therefor and application therefor as inhibitors of KRAS G12C for the treatment of cancers | KRAS, NRAS, GNAQ | DAO 4587/4885AXL 2727/4885NUDT1 422/4885 |
| US-12503467-B2 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors | MAT2B, MAT2A, MAT1A | DAO 1164/4885AXL 4213/4885NUDT1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.